Please assess the completion status of the following clinical trial:

Trial Title: PF-06651600 for the Treatment of Alopecia Areata

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of alopecia areata with no other cause of hair loss~* ≥50% hair loss of the scalp, including alopecia totalis and alopecia universalis, without evidence of terminal hair regrowth within 6 months~* Current episode of hair loss ≤10 years~Exclusion Criteria:~* Other types of alopecia or other diseases that can cause hair loss~* Other scalp diseases that could interfere with assessment of hair loss/regrowth~* Subjects with shaved heads must not enter the study until hair has grown back \& is considered stable by the investigator~* Any previous use of any Janus kinase (JAK) inhibitor

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sequence A (Type: EXPERIMENTAL): Induction dose given once daily (QD) for 4 weeks followed by maintenance dose #1 given QD for 44 weeks
- Sequence B (Type: EXPERIMENTAL): Induction dose given QD for 4 weeks followed by maintenance dose #2 given QD for 44 weeks
- Sequence C (Type: EXPERIMENTAL): Maintenance dose #1 given QD for 48 weeks
- Sequence D (Type: EXPERIMENTAL): Maintenance dose #2 given QD for 48 weeks
- Sequence E (Type: EXPERIMENTAL): Maintenance dose #3 given QD for 48 weeks
- Sequence F (Type: EXPERIMENTAL): Placebo given QD for 24 weeks followed by induction dose given QD for 4 weeks then maintenance dose #1 given QD for 20 weeks
- Sequence G (Type: EXPERIMENTAL): Placebo given QD for 24 weeks followed by maintenance dose #1 given QD for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).